Taiwan's TaiGen Biotechnology Company and German firm Cellex GmbH announced a collaborative agreement in clinical trial usage of Burixafor, yesterday. The Carl Gustav Carus University Hospital will also participate in the study titled "Burixafor in allogeneic poor mobilizers," which looks at the effect of a single dose of Burixafor.
http://ift.tt/1xynOJS
http://ift.tt/1xynOJS
No comments:
Post a Comment